Published in Cancer Weekly, February 13th, 2007
The compound will be tested for the treatment of cachexia in weight losing subjects with Stage IV, non-small cell lung cancer (NSCLC). The phase 2 clinical trial will be conducted in the United States and India, and is expected to be completed in Q3 2007.
This multicenter, randomized, open-label controlled study will assess the safety and efficacy of VT-122 regimen administered to weight...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.